Eysz

Eysz operates at the intersection of digital health, pediatric neurology, diagnostics, eye tracking, and machine learning. Its initial clinical focus is childhood absence epilepsy, where the company aims to supplement subjective clinical examinations and patient self-reporting with measurable eye-movement signals. The approach differs from conventional neurological assessment by treating eye movements as a digital biomarker for disease detection, progression, intervention response, and side-effect monitoring. Eysz’s product scope also includes ADHD assessment tools and software for digitally recording hyperventilation procedures and generating electronic reports for healthcare professionals. Its differentiation therefore rests primarily on its narrow pediatric epilepsy specialization, combination of eye-tracking data science and computational modeling, and clinician-led development model. NIH- and NSF-supported clinical work, a 2025 AAP Pediatric Innovation Award, and four granted patents provide external indicators of technical and clinical progress. However, its estimated employee count of fewer than 10 suggests an early-stage operating footprint relative to larger medtech and remote-monitoring companies.

Eysz’s trajectory shows a transition from research and early venture support toward focused clinical product development. The company was founded in 2018, followed by non-equity assistance in 2019 and a $1.95 million Seed round in 2020. A $707,000 grant later in 2020 and a $256,000 National Science Foundation grant in 2021 helped extend the research base. In 2022, Eysz recorded a Series A round with NeuroNetworks Fund and Celtic House Asia Partners, although the amount is not publicly specified. A $1 million grant in 2023 and a further $545,156 NIH SBIR Fast-Track grant on Oct 3, 2025 indicate continued reliance on non-dilutive research financing alongside private capital. The 2025 clinical-results announcement and AAP award represent important validation points, while the new NIH grant expands the stated direction from screening toward remote monitoring of childhood absence epilepsy. Eysz has also developed four granted patents related to provoking, monitoring, and managing neurological events. Growth remains difficult to quantify: the company lists fewer than 10 employees, has no reported hiring news, and public information does not establish commercial revenue, adoption, or a scaled deployment base.